Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson, Sisse R OstrowskiCapital Region Blood Bank, Section for Transfusion Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkBackground: Recombinant activated factor VII (rFVIIa, NovoSeven®) was introduced in 1996 for the treatment of hemophili...

Full description

Bibliographic Details
Main Authors: Pär I Johansson, Sisse R Ostrowski
Format: Article
Language:English
Published: Dove Medical Press 2010-06-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/evidence-supporting-the-use-of-recombinant-activated-factor-vii-in-con-a4697

Internet

http://www.dovepress.com/evidence-supporting-the-use-of-recombinant-activated-factor-vii-in-con-a4697

Similar Items